Baylor Scott & White Research Institute receives NIH award for esophageal cancer study

NewsGuard 100/100 Score

The incidence of esophageal adenocarcinoma has increased 8-fold over the past 50 years. This is one of the deadliest cancers, with a five-year survival rate of only 20 percent. However, the survival rate more than doubles if the cancer is identified early. Gastrointestinal reflux disease (GERD), which affects one in five adult Americans, is a major risk factor for esophageal adenocarcinoma via the precursor lesion Barrett's esophagus.

Aiming to find new ways to prevent esophageal cancer, a research team at Baylor Scott & White Research Institute received an R01 award from the National Institute of Diabetes and Digestive and Kidney Diseases one of the 27 institutes and centers of the National Institutes of Health (NIH), the nation's premier medical research agency, to study the molecular mechanisms that link GERD to Barrett's esophagus and cancer.

In particular, the research team wants to know why Barrett's esophagus frequently recurs after radiofrequency ablation, a minimally invasive endoscopic therapy that uses heat to destroy dysplastic cells. The answer seems to lie in the formation of subsquamous intestinal metaplasia, wherein Barrett's cells burrow under the normal squamous lining of the esophagus to evade ablation. They found that the acid and bile components of gastroesophageal reflux trigger the Barrett's cells to undergo epithelial-mesenchymal transition (EMT), a wound-healing event in which the cells acquire the ability to migrate under the squamous lining where they are hidden from endoscopists and shielded from destruction by radiofrequency ablation.

They hypothesize that EMT also helps the Barrett's cells survive after reflux-induced oxidative stress, a process that could allow oncogenic mutations to accumulate. Identifying strategies to prevent EMT or mitigate its cancer-promoting effects in Barrett's cells will guide the design of new therapies to prevent esophageal cancer.

Barrett's cells are predisposed to cancer but nobody really knows exactly why. Therefore, we are looking at what is happening in the esophagus when reflux is causing cancer-promoting damage to the Barrett's cells."

Stuart Spechler, MD, director of the division of gastroenterology at Baylor University Medical Center, co-director of the Center for Esophageal Research, and co-principal investigator on the R01 proposal

Rhonda Souza, MD, co-director of the Center for Esophageal Research and co-principal investigator on the R01 proposal, describes some of the data that inspired the current proposal. "We found that ursodeoxycholic acid, a non-toxic bile salt that is used to treat some liver diseases, can increase DNA repair in Barrett's cells through a signaling pathway involving P38 and APE1/Ref-1. This is one of several intriguing new molecular pathways that can be targeted for preventing mutation accumulations in Barrett's cells."

Other key signaling pathways under investigation include the hypoxia-inducible factors (HIFs). The 2019 Nobel Prize in Physiology or Medicine was awarded for the identification of hypoxia-inducible factors as multifunctional factors involved in sensing oxygen levels, including oxidative stress. The Baylor Scott & White research team previously discovered that HIF-2a mediates the response to GERD in normal esophageal epithelial cells. The new work focuses on HIF-1a in Barrett's cells. The researchers also have evidence that pathways involving the transcription factor ZEB1 link reflux to the initiation of EMT.

They are now planning to extend these studies and identify new drug targets both upstream and downstream of EMT. The work leading up to this proposal has been published in high impact journals including Gastroenterology and Gut. The importance of this mechanistic research is clearly shown in their prior work on GERD itself. According to Dr. Spechler, "We were able to completely change the paradigm of how reflux disease works. It was thought that the injury was just an acid burn, but we showed that the real damage comes from cytokines release in response to the refluxed acid. This was a brand new concept. Our research is translational and patient-oriented, focusing on fundamental mechanisms that underlie common disease processes. These are the kinds of studies needed to develop novel, effective treatments for our patients."

Dr. Souza is currently on the American College of Gastroenterology panel for establishing new national guidelines for treating Barrett's esophagus, and Dr. Spechler is on a similar American College of Gastroenterology panel for establishing national treatment guidelines related to GERD.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
NCCN 2024 Annual Conference focuses on practical applications for improving cancer care